Survival in synucleinopathies
- 3 November 2015
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 85 (18), 1554-1561
- https://doi.org/10.1212/wnl.0000000000002086
Abstract
Objectives: Parkinson disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF) involve cytoplasmic deposition of α-synuclein and are considered to be synucleinopathies. Approximately 40% of patients with PD, most patients with MSA, and all patients with PAF have neurogenic orthostatic hypotension (OH). This study compared long-term survival in these synucleinopathies. Methods: In this prospective cohort study, survival data were obtained for 97.6% of 206 referred patients evaluated between 1994 and 2014 (47 PD + OH, 54 PD no OH, 15 cerebellar MSA [MSA-C], 57 parkinsonian MSA [MSA-P], 28 PAF). Individual diagnoses were confirmed by clinical criteria and results of pharmacologic, neurochemical, and neuroimaging tests of sympathetic noradrenergic innervation. The Cox proportional hazard model was used to calculate hazard ratios (HRs) from symptom onset and from time of evaluation to death. Results: Patients with MSA-C or MSA-P had shorter survival from symptom onset than did patients with PD + OH (age- and sex-adjusted HR = 6.1, 5.6; p < 0.0001 each), PAF (HR = 10.8, 9.9; p < 0.0001 each) or PD no OH (HR = 14.9, 13.6; p < 0.0001 each). Among parkinsonian patients who died, median times from motor onset to death were 7.5 years in MSA-P, 11.6 years in PD + OH, and 15.8 years in PD no OH. Probabilities of survival for 10 years from onset of relevant symptoms were 0.39 in MSA-C, 0.33 in MSA-P, 0.74 in PD + OH, 0.87 in PAF, and 0.93 in PD no OH. Conclusions: In synucleinopathies, survival depends on the particular disease, with the risk of death greater in MSA-P than in PD + OH and in PD + OH than in PD no OH.Keywords
This publication has 23 references indexed in Scilit:
- Mortality and prognosis in patients with neurogenic orthostatic hypotension.2012
- The potential prognostic role of cardiovascular autonomic failure in α‐synucleinopathiesEuropean Journal of Neurology, 2012
- Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophyParkinsonism & Related Disorders, 2008
- Second consensus statement on the diagnosis of multiple system atrophyNeurology, 2008
- Dysautonomia in Parkinson's disease: neurocardiological abnormalitiesThe Lancet Neurology, 2003
- Neuropathological spectrum of synucleinopathiesMovement Disorders, 2003
- Survival of patients with pathologically proven multiple system atrophyNeurology, 1997
- Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophyClinical Autonomic Research, 1996
- Clinical features and natural history of multiple system atrophyBrain, 1994
- ParkinsonismNeurology, 1967